Engineered T cells: the promise and challenges of cancer immunotherapy
The immune system evolved to distinguish non-self from self to protect the organism. As
cancer is derived from our own cells, immune responses to dysregulated cell growth present …
cancer is derived from our own cells, immune responses to dysregulated cell growth present …
Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis
HE Teulings, J Limpens, SN Jansen… - Journal of Clinical …, 2015 - ascopubs.org
Purpose Vitiligo-like depigmentation in patients with melanoma may be associated with
more favorable clinical outcome. We conducted a systematic review of patients with stage III …
more favorable clinical outcome. We conducted a systematic review of patients with stage III …
Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
T Duhen, R Duhen, R Montler, J Moses… - Nature …, 2018 - nature.com
Identifying tumor antigen-specific T cells from cancer patients has important implications for
immunotherapy diagnostics and therapeutics. Here, we show that CD103+ CD39+ tumor …
immunotherapy diagnostics and therapeutics. Here, we show that CD103+ CD39+ tumor …
Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells
Therapeutic ex vivo T-cell expansion is limited by low rates and T-cell products of limited
functionality. Here we describe a system that mimics natural antigen-presenting cells (APCs) …
functionality. Here we describe a system that mimics natural antigen-presenting cells (APCs) …
Adaptive immune resistance emerges from tumor-initiating stem cells
Our bodies are equipped with powerful immune surveillance to clear cancerous cells as they
emerge. How tumor-initiating stem cells (tSCs) that form and propagate cancers equip …
emerge. How tumor-initiating stem cells (tSCs) that form and propagate cancers equip …
Enhanced cancer immunotherapy by chimeric antigen receptor–modified T cells engineered to secrete checkpoint inhibitors
Purpose: Despite favorable responses of chimeric antigen receptor (CAR)-engineered T-cell
therapy in patients with hematologic malignancies, the outcome has been far from …
therapy in patients with hematologic malignancies, the outcome has been far from …
[HTML][HTML] Targeting immune cells for cancer therapy
SY Gun, SWL Lee, JL Sieow, SC Wong - Redox biology, 2019 - Elsevier
Recent years have seen a renaissance in the research linking inflammation and cancer with
immune cells playing a central role in smouldering inflammation in the tumor …
immune cells playing a central role in smouldering inflammation in the tumor …
Current perspectives on nasopharyngeal carcinoma
Abstract Of the~ 129,079 new cases of nasopharyngeal carcinoma (NPC) and 72,987
associated deaths estimated for 2018, the majority will be geographically localized to South …
associated deaths estimated for 2018, the majority will be geographically localized to South …
Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric …
EK Moon, C Carpenito, J Sun, LCS Wang, V Kapoor… - Clinical cancer …, 2011 - AACR
Purpose: Adoptive T-cell immunotherapy with tumor infiltrating lymphocytes or genetically-
modified T cells has yielded dramatic results in some cancers. However, T cells need to …
modified T cells has yielded dramatic results in some cancers. However, T cells need to …
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1
NN Hunder, H Wallen, J Cao… - … England Journal of …, 2008 - Mass Medical Soc
We developed an in vitro method for isolating and expanding autologous CD4+ T-cell
clones with specificity for the melanoma-associated antigen NY-ESO-1. We infused these …
clones with specificity for the melanoma-associated antigen NY-ESO-1. We infused these …